Rare DiseasesValue/HTA26/06/2023 Recommendations for better use of quality of life evidence in HTA for rare diseases Download Presentation Share article:LinkedInEmailCopy Link HTAi Annual Meeting, 2023 — Elena Nicod Related articles Why orphan medicines remain out of reach in low- and middle-income countries – and what can be done Rare Diseases27/02/2026 Rare disease policy in high-income countries: An overview of achievements, challenges, and solutions European PolicyRare DiseasesUS Policy10/05/2025 What do the new Medicare negotiations mean for pipeline orphan therapies? Rare DiseasesUS Policy04/03/2025 Rare Disease Day 2025: How might JCA impact orphan sustainability in Europe? JCARare Diseases28/02/2025
Why orphan medicines remain out of reach in low- and middle-income countries – and what can be done Rare Diseases27/02/2026
Rare disease policy in high-income countries: An overview of achievements, challenges, and solutions European PolicyRare DiseasesUS Policy10/05/2025
What do the new Medicare negotiations mean for pipeline orphan therapies? Rare DiseasesUS Policy04/03/2025
Rare Disease Day 2025: How might JCA impact orphan sustainability in Europe? JCARare Diseases28/02/2025